| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Vassilis Baloumis CEO | XBER Exchange | - ISIN |
| DE Country | 300 Employees | - Last Dividend | 1 Aug 2022 Last Split | - IPO Date |
Lavipharm S.A., founded in 1911 and headquartered in Paiania, Greece, is an esteemed entity in the global healthcare industry, focusing on the research, development, manufacture, import, marketing, sale, and wholesale of a broad spectrum of pharmaceutical, dermocosmetic, and healthcare products. Catering to both the Greek market and an international clientele, the company has established itself as a key player in providing healthcare solutions directly to physicians and pharmacists. With a rich legacy spanning over a century, Lavipharm S.A. combines its profound experience with innovative practices to bring effective healthcare solutions to the forefront of the industry.
Lavipharm S.A. offers a diverse portfolio of pharmaceutical products targeting various critical areas of healthcare such as cardiology, oncology-urology, the central nervous system, and chronic pain management. This encompasses a range of medications designed to meet the therapeutic needs of patients, ensuring efficacy and safety across these core medical specialties.
Understanding the growing trend towards self-care, the company provides a selection of products aimed at self-treatment. These are designed to empower individuals to manage their health proactively, with over-the-counter (OTC) options that are both accessible and reliable, fostering a culture of wellness and preventive care.
Key to its product lineup, Lavipharm S.A. markets a variety of prescription medicines. These pharmaceuticals are developed based on rigorous research and adherence to industry standards, ensuring that healthcare professionals and patients have access to effective treatment options for a multitude of health concerns.
The range of over-the-counter (OTC) products offered by Lavipharm S.A. includes a vast selection of medications and health aids that can be purchased without a prescription. This segment enables consumers to address common health issues promptly and conveniently, enhancing the general wellbeing of the community.
Embracing the therapeutic potentials of cannabidiol (CBD), Lavipharm S.A. has ventured into the provision of LIFELAB CBD products. This line represents the company’s commitment to innovation in healthcare, offering scientifically-backed, CBD-infused solutions designed to support a range of health and wellness needs.